These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France. Noret M, Balavoine S, Pintado C, Siguier M, Brun A, Bauer R, Loze B, Leplatois A, Aslan A, Moudachirou K, Delaugerre C, Rozenbaum W, Molina JM. AIDS; 2018 Sep 24; 32(15):2161-2169. PubMed ID: 30212403 [Abstract] [Full Text] [Related]
25. Reactions and Receptivity to Framing HIV Prevention Message Concepts About Pre-Exposure Prophylaxis for Black and Latino Men Who Have Sex with Men in Three Urban US Cities. Mimiaga MJ, Closson EF, Battle S, Herbst JH, Denson D, Pitts N, Holman J, Landers S, Mansergh G. AIDS Patient Care STDS; 2016 Oct 24; 30(10):484-489. PubMed ID: 27749110 [Abstract] [Full Text] [Related]
26. Barriers to Oral PrEP: A Qualitative Study of Female Sex Workers, PrEP Prescribers, Policymakers, and Community Advocates in Morocco. Moussa AB, Badahdah AM, Hidous K, Barakad R, Diallo F, Traoré M, Khodabocus N, Ebsen Treebhoobun A, Delabre R, Rojas Castro D, Ouarsas L, Karkouri M. J Int Assoc Provid AIDS Care; 2024 Oct 24; 23():23259582241266691. PubMed ID: 39099547 [Abstract] [Full Text] [Related]
27. HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda. Koss CA, Havlir DV, Ayieko J, Kwarisiima D, Kabami J, Chamie G, Atukunda M, Mwinike Y, Mwangwa F, Owaraganise A, Peng J, Olilo W, Snyman K, Awuonda B, Clark TD, Black D, Nugent J, Brown LB, Marquez C, Okochi H, Zhang K, Camlin CS, Jain V, Gandhi M, Cohen CR, Bukusi EA, Charlebois ED, Petersen ML, Kamya MR, Balzer LB. PLoS Med; 2021 Feb 24; 18(2):e1003492. PubMed ID: 33561143 [Abstract] [Full Text] [Related]
28. Small-area spatial-temporal changes in pre-exposure prophylaxis (PrEP) use in the general population and among men who have sex with men in the United States between 2012 and 2018. Mouhanna F, Castel AD, Sullivan PS, Kuo I, Hoffman HJ, Siegler AJ, Jones JS, Mera Giler R, McGuinness P, Kramer MR. Ann Epidemiol; 2020 Sep 24; 49():1-7. PubMed ID: 32951802 [Abstract] [Full Text] [Related]
29. Knowledge of and willingness to take pre-exposure prophylaxis among men who have sex with men in Israel. Zohar M, Guy S, Itzchak L. Isr J Health Policy Res; 2021 Dec 06; 10(1):71. PubMed ID: 34872598 [Abstract] [Full Text] [Related]
31. Understanding PrEP Acceptability Among Priority Populations: Results from a Qualitative Study of Potential Users in Central Uganda. Sundararajan R, Wyatt MA, Muwonge TR, Pisarski EE, Mujugira A, Haberer JE, Ware NC. AIDS Behav; 2022 Aug 06; 26(8):2676-2685. PubMed ID: 35133529 [Abstract] [Full Text] [Related]
32. Barriers and facilitators to pre-exposure prophylaxis uptake among male sex workers in Mexico: an application of the RE-AIM framework. Kadiamada-Ibarra H, Hawley NL, Sosa-Rubí SG, Wilson-Barthes M, Franco RR, Galárraga O. BMC Public Health; 2021 Nov 27; 21(1):2174. PubMed ID: 34837988 [Abstract] [Full Text] [Related]
37. [Needs of pre-exposure prophylaxis for HIV infection and related barriers among men who have sex with men]. Shi AX, Operario D, Zhang ZH, Zhao Y, Zhu XF, Yang C, Zaller N, Gao P, Wang J, Sun YH, Zhang HB. Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Mar 10; 41(3):343-348. PubMed ID: 32294832 [Abstract] [Full Text] [Related]